People in Utah can now get a prescription for acne treatment written by an AI system that never examines them in person. On Monday, healthcare startup Nolla Health announced that residents of the state can scan their face with its app, let the AI grade the severity of their acne, and receive a prescription autonomously — a program Bloomberg first reported and The Verge confirmed with the company. The service costs $4.99 a month, is limited to Utah residents aged 18 and over with mild-to-moderate acne, and can currently prescribe eight different skin treatments.
What makes this a first is the word "initial." Several companies have been experimenting with AI-generated prescriptions in Utah, which began allowing AI systems to renew certain medications earlier this year: August AI was approved to pilot AI-assisted renewal of prescriptions for chronic conditions, and Doctronic has run an AI prescription refill pilot in the state. Nolla says it is the first in the country to have an AI issue the original prescription itself rather than refilling one a human doctor once wrote. That distinction matters — a renewal inherits a human's clinical judgment, an initial prescription replaces it.
The safety architecture is a phased loosening of physician oversight, and the company has published the thresholds. For the first 100 patients, two physicians approve each AI-generated prescription before it is issued. For the next phase, covering up to 500 patients, physicians review prescriptions only after they have already been dispensed. After that, the company says physicians review a sample of at least 10 percent of prescriptions every month, plus every case involving an escalation or a side effect. If the AI cannot "confidently select a treatment," the user is directed to a physician.
Read those numbers as an engineering document and the design is coherent: front-load human review where the model is least proven, then step it down as real-world evidence accumulates, and always audit escalations and adverse events. Read them as a patient and the arithmetic is harder to love. In steady state, roughly nine out of ten AI-prescribed scripts will face no contemporaneous human review at all — the 10 percent sample is retrospective, and the "every escalation or side effect" catch only triggers if something goes visibly wrong and gets reported. Automated systems fail in correlated, systematic ways; a monthly sample is a reasonable quality-control tool, but it is not a diagnosis of what the model is systematically missing.
The company's own framing concedes the trade. "The pilot is designed to complement, not replace, physicians," Nolla writes, arguing that "by handling routine, low-acuity cases, Nolla Derm frees dermatologists to focus on complex, high-risk patients." There is a real access case here — acne is one of the most common reasons people see a dermatologist, treatment is protocolized, and a $4.99 app is cheaper and faster than a referral queue. The risk is not that an AI handles mild acne badly in the average case; it is that the population that gets filtered out — the person whose "mild" acne is actually something else — depends on an AI confidence threshold nobody outside the company can inspect.
The broader read: Utah has effectively turned itself into the national test bench for autonomous prescribing, first with renewals and now with initial prescriptions, and every other state's medical board is watching the same experiment. The precedent being set is not that AI can write prescriptions — August AI and Doctronic already moved that line for renewals — but that the unit of regulatory proof is becoming a phase-gated pilot with published oversight thresholds rather than a clinical trial. Whether that is a faster, smarter path to safe deployment or a quieter way to normalize skipped review depends entirely on whether the escalation data ever gets published. Nolla should be pushed to make it public.
Comments (0)
Log in to join the discussion
Log InNo comments yet